List of works - Kohei Kaku

1Comparison in effects by three kinds of glucose-lowering drugs on nonalcoholic fatty liver disease in cases with type 2 diabetes: A randomized, open-label, 3-arm active-control study

scientific article published on 24 April 2020

A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at UBE2E2 and C2CD4A-C2CD4B

scientific article published on 05 September 2010

A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations

scientific article

Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin

scientific article published on 27 January 2020

Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss

scientific article published on 14 November 2019

Benefit-Risk Assessment of Alogliptin for the Treatment of Type 2 Diabetes Mellitus

scientific article published on 01 November 2019

Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial

scientific article published on 08 April 2019

Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes

scientific article published on 26 March 2018

Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial

scientific article published on 11 July 2019

Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: Results from a randomized, phase 3 study

scientific article published on 19 September 2019

Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study.

scientific article published on 2 July 2018

Impact of physical activity and sedentary time on HbA1c levels and body composition: Cross-sectional study using outpatient clinical data of Japanese patients with type 2 diabetes

scientific article published on 22 November 2019

Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.

scientific article

Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study

scientific article published on 19 November 2019

Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus

scientific article published on 7 November 2017

Long-term safety and efficacy of the sodium glucose cotransporter 2 inhibitor tofogliflozin added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus (J-STEP/GLP): a 52-week open-label, multicenter, post-mar

scientific article published on 28 May 2019

Long-term safety and efficacy of tofogliflozin add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicenter, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).

scientific article published on 5 January 2018

New concept of the glucagon-like peptide-1 signaling pathway on pancreatic insulin secretion

scientific article published on 25 September 2019

New prospects for incretin-related drugs in the treatment of type 2 diabetes

scientific article published on 05 November 2020

Pyogenic psoas abscess on the dorsal side and bacterial meningitis and spinal epidural abscess on the ventral side both of which were induced by spontaneous discitis in a subject with diabetes mellitus: A case report

scientific article published on 11 November 2020

Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status

scientific article published on 06 May 2019

SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations

article

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of J-STEP/LT, a 36-month post-marketing surveillance study

scientific article published on 29 June 2020

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT)

scientific article published on 08 July 2019

Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT)

scientific article published on 08 February 2020

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study)

scientific article published on 05 September 2019

Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

scientific article published on 11 January 2018

Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial

scientific article published on 28 August 2019

This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated"

scientific article published on 05 June 2018

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin

scientific article published on 24 November 2017

List of works by Kohei Kaku